Apogee Therapeutics Files Q1 2025 10-Q
Ticker: APGE · Form: 10-Q · Filed: May 12, 2025 · CIK: 1974640
| Field | Detail |
|---|---|
| Company | Apogee Therapeutics, Inc. (APGE) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech, agreements
Related Tickers: APGE
TL;DR
APGE Q1 2025 10-Q filed. Financials updated, includes ATM program & Paragon deal.
AI Summary
Apogee Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities, including details on its common stock and retained earnings. The filing also references agreements such as the Paragon IL-13 License Agreement and an At-The-Market Offering Program.
Why It Matters
This filing provides investors with an update on Apogee Therapeutics' financial health and ongoing business operations for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a biotechnology company, Apogee Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 20250512 — Filing Date (Date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Apogee Therapeutics, Inc. (company) — Filer of the 10-Q
- 0000950170-25-068513 (other) — Accession Number for the filing
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date
- ParagonTherapeuticsInc (company) — Related party mentioned in agreements
- ParagonIl13LicenseAgreement (other) — Specific agreement mentioned
- AtTheMarketOfferingProgram (other) — Financing program mentioned
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 12, 2025.
What specific agreements are mentioned in the filing?
The filing mentions the Paragon IL-13 License Agreement and an At-The-Market Offering Program.
What is Apogee Therapeutics, Inc.'s Standard Industrial Classification?
Apogee Therapeutics, Inc.'s Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
What is the company's business address?
The company's business address is 221 Crescent St., Building 17, Suite 102B, Waltham, MA 02453.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Apogee Therapeutics, Inc. (APGE).